Impact of genomic assays on treatment and outcomes in locally advanced breast cancer.
Omar PicadoDeukwoo KwonKristin RojasJessica CrystalLora WangReshma MahtaniFrances ValdesNeha GoelSusan B KesmodelPublished in: Breast cancer research and treatment (2022)
In women with LABC and low genomic risk, endocrine therapy alone was associated with worse OS compared to chemoendocrine therapy. This suggests that genomic profiling is not predictive in LABC. Accordingly, genomic profiling should not be routinely utilized to make adjuvant treatment decisions in LABC in the absence of further data which shows a benefit.